Introduction: As standard care of severe haemophilia A (SHA), prophylaxis should be individualised.Aim: This study aimed to investigate the effectiveness of this new‐proposed individualised prophylaxis protocol.Methods: Boys with SHA were enrolled and followed a PK‐guided, trough‐level escalating protocol of prophylaxis after a six‐month observational period. In the next 2 years, clinical assessments including joint bleeds, ultrasound (US) scores and Haemophilia Joint Health Score (HJHS) in both sides of ankles, knees and elbows were conducted every 6 months as a scoring system, which determined whether the trough level's escalation. Adjustment of dosing regimen was based on WAPPS‐Hemo.Results: Fifty‐eight SHA boys were finally analysed. Their age and bodyweight were 5.3(2.8,6.9) years and 21.5(16,25) kg. During the study, 47 escalations were conducted. At study exit, the patient number and proportion of different trough level groups were: < 1 IU/dl, 17.2% (10/58); 1–3 IU/dl, 53.5% (31/58); 3–5 IU/dl, 15.5% (9/58); > 5 IU/dl, 13.8% (8/58). Significantly reduced annualised bleeding rate [4(0,8) to 0(0,2), p < .0001] and annualised joint bleeding rate [2(0,4) to 0(0,.25), p < .0001] was observed at study exit as well as the continuous trend of increased zero bleeding proportion (ZBP) (27.6%–69.0%) and zero joint bleeding proportion (46.5%–81.3%). Besides, 85% (6/7) of the target joints vanished. Statistical improvements of US scores (p = .04) and HJHS (p = .02) were also reported at study exit.Conclusion: Our results showed the effectiveness of our protocol based on individualised target trough level and emphasise the importance of personalised prophylaxis.
No studies evaluated the role of F8 mutations in outcomes for low‐dose immune tolerance induction (ITI) in people with severe hemophilia A (SHA) with high‐titer inhibitors. To explore the association between F8 mutation types and low‐dose ITI outcomes in children with SHA with high‐titer inhibitors. Children SHA with high‐titer inhibitors who received low‐dose ITI therapy at least for 1 year were included in this study. Based on the risk of inhibitor development, F8 mutations were classified into a high‐risk group and a non–high‐risk group. Rapid tolerance and the final ITI outcomes were assessed at the 12th and 24th month of treatment, respectively, and the predictor of outcomes was analyzed. Of 104 children included, 101 had F8 mutations identified. The children with non–high‐risk mutations presented a higher rate of rapid tolerance than those with high‐risk mutations (61.0% vs. 29.2%; p = 0.006). Among 72 children beyond 24 months of ITI, 55 children (76.4%) achieved success, 3 (4.2%) achieved partial success, and 14 (19.4%) failed. The children in the non–high‐risk group showed a higher success rate (86.8% vs. 43.8%; p = 0.001) and a shorter time to success (mean time, 9.3 months vs. 13.2 months; p = 0.04) compared to those in the high‐risk group. In multivariable logistic regression, F8 mutations were an independent predictor of ITI success (non–high‐risk group vs. high‐risk group, adjusted odds ratio [OR], 20.3; 95% confidence interval [CI], 3.5–117.8), as was the interval from inhibitor diagnosis to ITI start (adjusted OR, 0.95; 95% CI, 0.90–0.99). They remained the significant predictors when success time was taken into account in a Cox model. Types of F8 mutation were a key predictor of outcomes for low‐dose ITI in children with SHA with high‐titer inhibitors. It can help to stratify the prognosis and guide clinical decisions.
Background: In 2020, the hemophilia care team at Beijing Children’s Hospital initiated a study entitled LEAPS (Pharmacokinetics and complementary evaluation system-based recommendations on prophylaxis for pediatric patients with hemophilia A in China using Kovaltry). This paper presents the results of a two-year follow-up research on children with hemophilia A from the LEAPS program.Objective: Clinical follow-up was based on the LEAPS protocol. Patients will get periodic joint evaluations, FVIII trough level measurements, and pharmacokinetic (PK) tests. A dose escalation prophylaxis treatment plan will be implemented based on the PK test results and the graded low-dose prophylaxis therapy program.Patients/Methods: Clinical follow-up was based on the LEAPS protocol. 60 patients got periodic joint evaluations, factor VIII (FVIII) trough level measurements, and PK tests. A dose escalation prophylaxis treatment plan was implemented based on the PK test results and the graded low-dose prophylaxis therapy program.Results: 60 children diagnosed with severe hemophilia A two-year follow-up was conducted. Zero bleeding rate (ZBR) and zero joint bleeding rate (ZJBR) climbed from 68.33% and 45% pre-enrollment to 76.67% and 58.33% at the first-year follow-up, and further ascended to 80.00% and 70.00% at the second-year follow-up. The average ultrasonography score per joint at enrollment was 0.62, which declined to 0.49 by the conclusion of the two-year follow-up.Conclusions: The 2-year follow-up results of 60 hemophilia A patients in LEAPS confirmed the long-term efficacy of prophylaxis treatment guided by PK and comprehensive evaluation system in reducing bleeding events, maintaining joint health, and improving the quality of life of patients.